1. Emerging Atopic Dermatitis Treatments:

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

3. Atopic Dermatitis

4. Hypotheses of Atopic Dermatitis

5. Atopic Dermatitis and Immune Dysfunction

6. Skin Barrier Dysfunction

7. Immune System Dysfunction

8. Crisaborole Topical PDE4 Inhibitor

9. Crisaborole Topical PDE4 Inhibitor (cont)

10. Patient Education

11. Apremilast Oral PDE4 Inhibitor

12. Dupilumab IL-4 Receptor α Inhibitor

13. Dupilumab IL-4/IL-13 Inhibitor

14. Dupilumab IL-4/IL-13 Inhibitor

15. Dupilumab Pediatric Studies

16. IL-13 Inhibitors Lebrikizumab and Tralokinumab

17. Lebrikizumab and Tralokinumab

18. Nemolizumab IL-31 Receptor Inhibitor

19. Nemolizumab

20. JAK Inhibitors Baricitinib and Tofacitinib

21. JAK Inhibitors

22. Patient-Centric Management of AD

23. The AD Tool Kit

24. Concluding Remarks

25. Abbreviations